The leadership change at the New Haven, Connecticut-based firm elevates Randy Teel, 47, who previously served as Arvinas’ chief business officer. Teel joined the company in 2018 and has played a key role in its business development strategy before taking the top executive spot. According to the company, his new compensation package includes a $680,000 base salary and a target annual cash bonus set at 60% of that base pay.

John Houston, who has served as president and CEO since 2017, will remain a member of the board and transition into a consultancy role. Houston also stepped down from his position as chairman, which he had held since June 2023. His departure from day-to-day operations marks the end of a seven-year tenure during which Arvinas established itself as a significant player in targeted protein degradation.

Strategic Board Appointments

As part of the reorganization, Arvinas named Briggs Morrison as the new chairman of the board. Morrison has been a director since June 2018 and previously served as the lead independent director. This move is intended to ensure continuity in governance as the company continues to navigate the complexities of its clinical-stage pipeline.